Hoda Kotb Shares Scary Update About Her Daughter's Health
Hoda Kotb Shares Scary Update About Her Daughter's Health originally appeared on WeHaveKids.
We finally know the real reason behind Hoda Kotb's decision to leave her spot at NBC. The mother of two made the announcement while appearing on the Today show, sharing with fans how her daughter Hope's recent health struggles had been a major driver in her decision to step down. The good news is that Hope is doing well now, but it sounds like she has a lifetime of monitoring her health to ensure that she stays that way.
Related: Jenna Bush Hager Lists Things She's 'Done With' As a Mom and It's Spot-On
According to the doting mom, Kotb's 5-year-old daughter had been diagnosed with Type I diabetes more than a year ago. Kotb talked about the diagnosis, and how her constant worrying about how she was doing at home led her to step down from her position at NBC.
'As anyone with a child who has Type I [knows], especially a little kid, you're constantly watching, you're constantly monitoring, you're constantly checking, which is what I did all the time when I was [at 'Today.'] You're distracted,' Kotb explained, adding that the diagnosis had her rethinking her priorities as a working mom.
"I can be here and sweating what's happening to Hope in the morning and in the night, or I can be there and feel relief that I can see,' she continued, nothing that her daughter is fine most of the day, but there are times when she needs a bit more attention from her mother.
Fortunately, those large chunks of time where Hope is okay is what gets Kotb through the day, according the mom, who said she did the math and discovered that her daughter has 23.5 good hours a day.
"So, for 23 and a half hours, she's every other kid. So I try to remember that.'
While Kotb did reiterate that Hope's health was in good shape these days, and even explained how her daughter had been able to reduce the amount of insulin needed each day over the past year, she does still worry about her little girl... as any mom would.
Here's hoping that Kotb and her family continue to be in good health, and that the proud mama enjoys this extra time with her family, even if it did come as a result of something scary and stressful.
Up Next: Hoda Kotb Shares Scary Update About Her Daughter's Health first appeared on WeHaveKids on May 30, 2025
This story was originally reported by WeHaveKids on May 30, 2025, where it first appeared.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Four-year data show preservation of cardiac function, including LVEF Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) Deramiocel's long-term safety profile remains favorable Results presented at PPMD's 2025 Annual Conference SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive four-year safety and efficacy results from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be featured in the session titled 'Therapies that Slow Progression' at the Parent Project Muscular Dystrophy (PPMD) 2025 Annual Conference, taking place June 21, 2025, in Las Vegas, Nevada. After four years of continuous treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline. Further, a subgroup analysis of patients with baseline LVEF >45% showed an even greater clinical benefit, supporting early intervention with Deramiocel to potentially preserve cardiac function. Additionally, treatment continued to slow skeletal muscle disease progression, as measured by Performance of the Upper Limb (PUL v2.0), with patients experiencing a smaller average decline in the fourth year (0.6 points) compared to the first year (1.8 points). Together, these findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time. Deramiocel continues to maintain a favorable safety profile throughout the study. 'Cardiomyopathy remains one of the leading causes of mortality in Duchenne and addressing this aspect of the disease is critical to improving outcomes,' said Pat Furlong, Founding President and CEO of PPMD. 'The long-term data from the HOPE-2 OLE study are encouraging, particularly in demonstrating cardiac stabilization over four years. Deramiocel represents an important therapeutic approach and we support continued progress through the regulatory pathway to ensure that treatments targeting both heart and muscle function are available to our community as quickly as possible.' 'These four-year data reinforce the strength and durability of Deramiocel's clinical benefit and favorable safety profile across both cardiac and skeletal muscle function,' said Linda Marbán, Ph.D., CEO of Capricor Therapeutics. 'With our BLA under priority review and several key regulatory steps now completed, we are executing with focus and urgency as we move toward potential approval. Our continued dialogue with the FDA remains on track with no evidence of any delays. We thank the patients, families, and clinicians who have been instrumental in advancing this program.' The PPMD Annual Conference is the largest international event focused on advancing research, clinical trials, and standards of care for Duchenne and Becker muscular dystrophies. Capricor's presentation will be available following the conference in the publications section of the Company's was a randomized, double-blind, placebo-controlled Phase 2 study of Deramiocel in boys and young men with Duchenne Muscular Dystrophy (DMD). Patients received intravenous infusions of either Deramiocel (150 million cells) or placebo every three months. The results were published in The Lancet. Following study completion, all patients entered a treatment gap phase for approximately 392 days (range: 239–567). Eligible patients then enrolled in the HOPE-2 OLE study, receiving Deramiocel every three months. The OLE study previously met its primary endpoint at one year with statistically significant improvement on the PUL v2.0 (p=0.02). Now in its fifth year, the HOPE-2 OLE study remains ongoing, with participants continuing to be monitored for safety, cardiac function, and upper limb Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD. There is no cure, and treatment options remain (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in dystrophiopathies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing, rather than a pro-inflammatory phenotype. CDCs have been investigated in more than 250 peer-reviewed scientific publications and administered to over 250 human subjects across multiple clinical trials. Deramiocel has received Orphan Drug Designation for the treatment of Duchenne Muscular Dystrophy (DMD) from both the U.S. FDA and the European Medicines Agency (EMA). In addition, it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., Advanced Therapy Medicinal Product (ATMP) designation in Europe, and Rare Pediatric Disease Designation from the FDA, which may qualify Capricor for a Priority Review Voucher upon approval. For Becker Muscular Dystrophy (BMD), Deramiocel has also received Orphan Drug Designation from the Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy. Extensive preclinical and clinical studies have shown Deramiocel to exert potent immunomodulatory and anti-fibrotic actions in the preservation of cardiac and skeletal muscle function in muscular dystrophies such as DMD. Deramiocel is currently in late-stage development for the treatment of Duchenne Muscular Dystrophy. Capricor is also harnessing the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases. At Capricor, we stand committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit and follow Capricor on Facebook, Instagram and in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; statements about our financial outlook; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; plans regarding current and future collaborative activities and the ownership of commercial rights; potential future agreements; scope, duration, validity and enforceability of intellectual property rights; future revenue streams and projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words 'believes,' 'plans,' 'could,' 'anticipates,' 'expects,' 'estimates,' 'should,' 'target,' 'will,' 'would' and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the Securities and Exchange Commission on May 14, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements. Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel is an Investigational New Drug (IND) and is not yet approved for any indications. Neither BMD nor any of Capricor's exosome-based candidates have been approved for clinical Media Contact:Raquel ConaKCSA Strategic Communications rcona@ Capricor Company Contact:AJ Bergmann, Chief Financial Officerabergmann@
New York Post
a day ago
- New York Post
Jenna Bush Hager reveals topless sunbathing once left her chest green — dermatologist reveals why
Here's another reason to slather on some SPF this summer — especially if you're planning to bare it all. Jenna Bush Hager revealed this week that a trip to a topless beach in Spain during high school left her so scorched, her chest turned green. 'If you get burned, it's not pretty,' the 43-year-old 'Today With Jenna & Friends' co-host told actress Leslie Bibb on Tuesday's episode. 5 Actress Leslie Bibb appeared on the June 16 episode of 'Today With Jenna & Friends.' NBC When Bibb, 51, asked if her chest peeled, Bush Hager nodded — but then took things in a bizarre turn. 'They may have turned green,' the TV personality said. 'The opposite of the color wheel!' 'They turned green? Are you for real life?' the White Lotus star gasped. 'Oh, I don't think that's good,' Bibb added — and she's probably right. Sunburns happen when you're exposed to too much ultraviolet (UV) light, which can penetrate into deep layers of the skin and cause cellular damage, according to the Mayo Clinic. The body responds by increasing blood flow to the area, leading to inflamed skin we know as a burn. 'Signs that your burns are significant include painful redness, peeling and blisters,' Dr. Lauren Taglia, a dermatologist, told Northwestern Medicine. In Bush Hager's case, her Elphaba-esque chest may have signaled something more serious going on beneath the surface. 5 Bush Hager's chest 'turned green' after a bad sunburn. NBC 5 'Green!' Bibb exclaimed. 'That… makes me sick.' TODAY with Jenna & Friends / TikTok 'When the skin barrier is significantly damaged from a bad sunburn, it's possible to develop a secondary bacterial infection,' Dr. Adarsh Vijay Mudgil, medical director of Mudgil Dermatology, told The Post. Mudgil hasn't treated Bush Hager personally, but he speculated that her symptoms could be caused by impetigo, a common and contagious bacterial skin infection. 'This can lead to the formation of yellowish-green crusts, which would explain the green color she described,' Mudgil explained. 'Impetigo can be painful and requires antibiotics for treatment, either topical or systemic, depending on how widespread the infection is,' he noted. Gross? Bush Hager agrees. 5 All skin types can burn, though those with a lighter complexion are more at risk. Evgen – The former first daughter said the experience was enough to scare her away from sunbathing for good. 'I try not, but this is years of sun damage,' she admitted, rubbing her arms and adding that she now gets regular skin checks. She also offered some sage advice for viewers: wear sunscreen, especially when you're young. 'SPF babies, SPF! Get hip with it!' Bibb chimed in. Dermatologists agree. For daily use, most experts recommend using sunscreen with an SPF of at least 30. If you're spending extended time outdoors, SPF 60 or higher is smart, according to Johns Hopkins Medicine. For full-body coverage, aim for about one ounce of sunscreen — roughly a shot glass. And don't forget to reapply every two hours, or more if you're swimming or sweating. Even if you're inside, you're not off the hook. 5 Hager Bush, a mom-of-three, wishes her younger self hadn't tanned so much. Instagram/jennabhager 'Most ultraviolet (UV) rays can penetrate glass, so if you're working or relaxing near a window, you're receiving sun exposure,' Dr. Elisabeth G. Richard, a dermatologist, told the Skin Cancer Foundation. The bright side: you won't have to reapply as frequently as you would outdoors, likely every four to six hours. 'Sun damage is cumulative,' Richard noted. 'So even if you're only exposed for a short time, it's important to have protection.' Experts also recommend doubling up with wide-brimmed hats, sunglasses and protective clothing for extra coverage. When the sun's at its peak — between 10 a.m. and 2 p.m. — your best bet is to head for the shade. And if a green chest isn't warning enough, don't forget: Every sunburn — even a mild one — increases your risk of skin cancer, including melanoma, the deadliest form of all. In fact, just one blistering burn in childhood or adolescence more than doubles your risk of melanoma later in life, according to the Skin Cancer Foundation. The American Cancer Society estimates that in 2025, 104,960 new melanoma cases will be diagnosed in the US — and 8,430 Americans will die from it.
Fox News
3 days ago
- Fox News
'Grey's Anatomy' alum Eric Dane prepared to go to extreme measures to fight ALS
Eric Dane is prepared to go to extreme measures to fight ALS. "I will fly to Germany and eat the head off a rattlesnake if [doctors] told me that that would help," the 52-year-old "Grey's Anatomy" alum told Diane Sawyer during a sit-down interview on "Good Morning America." "I'll assume the risk." During the interview, which aired Tuesday, Dane opened up about the debilitating disease and explained how he's found hope in the physician who has been leading his care. "I'm very hopeful... I don't think this is the end of my story," he said. "And whether it is or it isn't, I'm gonna carry that idea with me. "That's what I got from [Dr. Merit Cudkowicz] when I met her... there was a sense of hope I didn't get from other doctors that I met with," Dane said of his doctor, a neurologist and leading ALS researcher. Dane said that he had spoken previously with an organization that told him his doctors would be "there to... monitor my decline — and that's not very helpful." Dr. Cudkowicz said the risk factors behind the disease can include anything from environmental concerns like plastics and bacteria in lakes to sports injuries. "We worry about head trauma because we do see ALS more common in people in certain sports like football or soccer. We worry about pesticides as well. Being in the military is a risk factor," she said. "Those are the ones we know about, but there's many more we don't know about. "There's people all over the world working on this," she said, referring to ALS research. "Between artificial intelligence and other imaging technology, that's what gets me excited, and that's all coming in the next, I think, one to two years, if not faster." Dane, who revealed his diagnosis in April, said in another segment of the interview that aired Monday that he first started experiencing weakness in his right hand before seeking medical attention. "I didn't really think anything of it at the time," he told Sawyer. "I thought maybe I'd been texting too much and my hand was fatigued. A few weeks later, I noticed it'd gotten a little worse. I went and saw a hand specialist, who sent me to another hand specialist. I went and saw a neurologist, and the neurologist sent me to another neurologist and said, 'This is way above my pay grade.' "I have one functioning arm," he said. "My left side is functioning. My right side has completely stopped working. [My left arm] is going. I feel like maybe a couple, a few more months, and I won't have my left hand either. It's sobering." He said that for now, he is able to walk, but added, "I'm worried about my legs." Dane admitted that he will "never forget" the moment he was diagnosed. "I will never forget those three letters, [ALS]. It's on me the second I wake up," he said. "It's not a dream." The actor, who shares two daughters, Billie, 15, and Georgia, 13, with wife Rebecca Gayheart, said he began noticing more of the effects of his disease a few months ago during a boating trip with his daughter. After jumping into the water, Dane — a former competitive swimmer — quickly realized he was not able to swim. "[Georgia] dragged me back to the boat," said Dane, who recalled immediately breaking down in tears once on the boat. "I was just, I was, like, heartbroken." Dane also told Sawyer that he is "angry" about the diagnosis, explaining, "I'm angry because my father was taken from me when I was young, and now there's a very good chance that I'm going to be taken from my girls while they're very young." "I mean, I really, at the end of the day, just, all I want to do is spend time with my family and work a little bit if I can," he added. Fox News Digital's Janelle Ash contributed to this post.
